Nautilus Biotechnology, Inc. reported a net loss of $15.0 million for the second quarter of 2025, a decrease from the $18.0 million loss recorded in the same period of 2024. For the first half of 2025, the company’s net loss totaled $31.6 million, down from $36.7 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which fell to $17.1 million in Q2 2025 from $20.8 million in Q2 2024, primarily due to cost optimization efforts, including a reduction in workforce. Research and development expenses decreased by 16% year-over-year, while general and administrative expenses dropped by 20%.
In terms of financial position, Nautilus reported total assets of $213.2 million as of June 30, 2025, down from $242.7 million at the end of 2024. The company’s cash and cash equivalents increased to $34.5 million, alongside short-term investments of $113.4 million. However, the accumulated deficit rose to $304.7 million, reflecting the ongoing investment in research and development for its proteomics platform, which remains in the development stage. The company has not yet generated any revenue from product sales.
Operationally, Nautilus is focused on advancing its proteomics platform, which is designed to enhance the analysis of proteins for applications in human health and medicine. The company is currently in the collaboration phase of its three-phase commercial launch strategy, engaging with a limited number of research customers to validate its technology. Nautilus plans to expand its commercial infrastructure to support sales and distribution, with a target for broader commercialization expected in late 2026.
Looking ahead, Nautilus anticipates that its expenses will continue to rise as it invests in research and development, establishes sales and marketing capabilities, and expands its intellectual property portfolio. The company has indicated that it will require substantial additional funding to support its operations and development efforts, with plans to raise capital through equity or debt financing. Nautilus has also entered into a sales agreement to potentially offer up to $125 million in common stock, although no shares have been sold under this agreement to date. The company is actively monitoring market conditions and its financial position to ensure it can meet its operational needs.
About Nautilus Biotechnology, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.